Professor School of Innovation and Entrepreneurship

Dr. David (Dongliang) Ge is Professor at Southern University of Science and Technology (SUSTech). He is also Chairman of SUSTech-Apostle joint venture, as well as Chairman, CEO and co-Founder of Apostle Inc (, a Silicon-Valley-based biotechnology company focusing on liquid biopsy technologies.

Personal Profile


  • Named by Phacilitate as one of the "Top 50 Most Influential People in Big Data" in 2015
  • Named by the Genome Technology magazine as the “Rising Stars” in 2009
  • 20 years of experience in bioinformatics, genomics, and biomarker
  • Published 5 articles in Nature and 1 in Science; work in total receiving over 18,000 citations. 
  • Contributed to the bioinformatics and biomarker section of the U.S. FDA Guidelines for Industry: Enrichment Strategies; Chronic HCV infection
  • Patent inventor of genomic biomarker products: Quest AccuType® IL28B,LabCorp 480630
  • Contributed to the clinical development of Sofosbuvir, a world-leading drug
  • Member of U.S. NIH NHGRI Special Emphasis Panel
  • CEO and co-founder of Apostle Inc, a Silicon-Valley-based biotechnology company developing liquid biopsy technologies.
    • A BioSpace top 20 Biotech Startups 2018
    • A Stanford University StartX company 2018
  • President, BioSciKin/Simcere Diagnostics Co., Ltd.; led a 200-people company; oversee the investment in 3 of the "50 Smartest Companies 2016 - MIT Technology Review", and 2 of the 3 European Biotech Unicorns in 2016, with a focus on bioinformatics, genomics, and precision medicine
  • Former Director of Bioinformatics, Gilead Sciences, Inc.; Head of Bioinformatics Department
  • Former Assistant Professor of Medicine, Biostatistics and Bioinformatics, Duke University School of Medicine
  • Author of a series of software tools for next-generation sequencing studies; Experienced JAVA and R programmer


Educational and Training Background

  • Duke University, USA: Postdoctoral fellow                                          2006- 2008
    • Bioinformatics and Biostatistics
    • Next generation sequencing studies; Genome-wide association studies
    • Precision Medicine; Pharmacogenomics
    • Clinical trial
  • Medical College of Georgia, USA: Postdoctoral fellow                        2005- 2006
    • Structural Equation Modeling
    • Genomics; Pharmacogenomics
  • Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. 2004.
    • PhD. Biostatistics and Genetic Epidemiology/Bioinformatics.
    • National recommendation
  • Shanghai Medical University (currently Fudan University School of Medicine), Shanghai, China.  1999.
    • MD.
    • First Prize, the National People Scholarship


The research direction of Professor Ge's team is to develop and apply revolutionary new genomic detection technology and computer analysis technology, so as to fundamentally solve some key challenges in the clinical application of genomic detection, so as to improve the global human health. The future development plan of scientific research can be divided into three levels:

(1) a number of new chemical and biochemical materials and methods are used to achieve the high-efficiency enrichment, preservation, extraction and targeted operation of trace genetic substances in human body fluids such as plasma, serum, saliva, urine and cerebrospinal fluid. As a platform technology, it can be applied in a wide range of genetic material analysis fields.

(2) the cancer big data platform and artificial intelligence machine learning technology ensure that the deep machine learning from high-quality cancer genome big data is accurate and efficient, and effectively solve the problem of high heterogeneity of tumor genome. Based on artificial intelligence technology, we can accurately identify circulating tumor DNA in the samples, and then realize the diagnosis of early cancer.

(3) organic integration of the above chemical and biochemical materials and methods with artificial intelligence machine learning technology The purpose is to achieve the accurate and efficient enrichment of tumor DNA fragments in the samples, and analyze these DNA fragments accurately for the diagnosis of early cancer. After fusion, compared with the traditional plasma free DNA enrichment technology, this technology can specifically enrich tumor DNA, remove the background noise of DNA fragments from normal tissues, improve the accuracy of tumor DNA analysis, reduce the sequencing depth and cost, and make the early diagnosis of cancer with high accuracy and low cost possible.

Publications Read More

Prior to Apostle, he was President of BioSciKin Co., Ltd., a China-based biotechnology company focusing on biomedical innovation, incubating, investing and licensing. Between 2011 and 2016, he was Director of Bioinformatics at Gilead Sciences, where he provided leadership to the corporate bioinformatics group and provided strategic input to the precision medicine infrastructure and process. Between 2008 and 2011, he was appointed as Assistant Professor of Medicine, Biostatistics and Bioinformatics at Duke University School of Medicine. He was also appointed as member of U.S. NIH NHGRI Special Emphasis Panel. He received his PhD of Biostatistics and Genetic Epidemiology from Chinese Academy of Medical Sciences in 2004. At Gilead, he and his colleagues contributed to the clinical development of Sofosbuvir, a world-leading anti-HCV drug. His work in discovering the IL28B genetic variants associated with clinical response, published in Nature in 2009, has received over 3000 citations to date. In total, his work, including co-authoring 5 original articles in Nature and 1 in Science, has received over 17,000 citations. Dr. Ge was named by the U.S. Genome Technology magazine as one of the “rising stars” in 2009 and by the U.K. Phacilitate as one of the “Top 50 Most Influential People in Big Data” in 2015. In 2018, BioSpace named Apostle Inc as one of the “Top 20 Life Science Startups to Watch”.

Lab members Read More

Join us

Contact Us

Contact Address

Office Phone



Copyright © 2018 All Rights Reserved.